What are the key practice‑changing clinical trials of dapagliflozin (SGL‑2 inhibitor), and what were their efficacy results and safety pitfalls?

Practice-Changing Trials of Dapagliflozin: Results and Pitfalls

Dapagliflozin has demonstrated robust mortality and morbidity benefits across three major disease states—heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease—establishing it as a cornerstone therapy regardless of diabetes status.

Key Practice-Changing Trials

DAPA-HF (Heart Failure with Reduced Ejection Fraction)

Trial Design & Population:

• 4,744 patients with symptomatic HFrEF (LVEF ≤40%, NYHA class II-IV)
• 58% without diabetes
• Median follow-up: 18 months
• Excluded patients with eGFR <30 mL/min/1.73 m² 1

Results:

• Primary endpoint (CV death or HF hospitalization): 26% reduction (HR 0.74,95% CI 0.65-0.85; P <0.001) 2
• HF hospitalization alone: 30% reduction (HR 0.70,95% CI 0.59-0.83) 1
• Cardiovascular death: 18% reduction (HR 0.82,95% CI 0.69-0.98) 2
• All-cause mortality: 17% reduction (HR 0.83,95% CI 0.71-0.97) 1
• Benefits were identical in diabetic (HR 0.75) and non-diabetic patients (HR 0.73) 2
• Quality of life improved and blood pressure reduced by ~2 mmHg 1

DELIVER (Heart Failure with Preserved Ejection Fraction)

Trial Design & Population:

• 6,263 patients with symptomatic HFnrEF (LVEF >40%)
• Median follow-up: 2.3 years 3

Results:

• Primary endpoint (CV death, HF hospitalization, or urgent HF visit): 18% reduction (HR 0.82,95% CI 0.73-0.92) 3
• Driven primarily by reduction in worsening HF events (HR 0.79,95% CI 0.69-0.91)
• No heterogeneity by sex, LVEF, or diabetes status 3

DAPA-CKD (Chronic Kidney Disease)

Trial Design & Population:

• 4,304 patients with CKD (eGFR 25-75 mL/min/1.73 m²)
• UACR 200-5,000 mg/g
• 67.5% had type 2 diabetes; 32.5% had CKD without diabetes
• Median follow-up: 2.4 years 4, 1

Results:

• Primary composite outcome (≥50% sustained eGFR decline, ESKD, or renal/CV death): 44% reduction (HR 0.56,95% CI 0.45-0.68; P <0.001) 1
• Renal composite alone: 44% reduction (HR 0.56,95% CI 0.45-0.68) 4
• CV death or HF hospitalization: 29% reduction (HR 0.71,95% CI 0.55-0.92; P = 0.009) 1
• All-cause mortality: 31% reduction (HR 0.69,95% CI 0.53-0.88; P = 0.004) 1

DECLARE-TIMI 58 (Diabetes with CV Risk)

Trial Design & Population:

• 17,160 patients with type 2 diabetes
• Established ASCVD or multiple CV risk factors
• Only 10-14% had baseline heart failure 5, 6

Results:

• HF hospitalization: 32% reduction across all SGLT2i trials (HR 0.68,95% CI 0.61-0.76) 6
• CV death or HF hospitalization: 22% reduction (HR 0.78,95% CI 0.73-0.84) 6
• Benefits consistent regardless of baseline ASCVD presence 6

Critical Safety Pitfalls and Mitigation Strategies

Common Adverse Events (Manageable)

Genital Mycotic Infections (Most Common):

• Women: 10-15% risk
• Uncircumcised men and those with prior infections at highest risk
• Management: Typically managed with antifungal drugs without discontinuation 1
• Daily hygiene to keep genital area clean and dry 7

Urinary Tract Infections:

• Increased risk but generally manageable 1

Serious Adverse Events (Rare but Important)

Diabetic Ketoacidosis (DKA):

• Incidence: 0.1% in trials 1
• Can present with normal or only modestly elevated glucose (<14 mmol/L) 1
• Contraindicated in type 1 diabetes 1
• Mitigation: "STOP DKA" protocol—stop SGLT2i, test for ketones, maintain fluid/carbohydrate intake, adjust insulin 7
• Hold during acute illness (nausea, vomiting, diarrhea) 7

Fournier's Gangrene (Necrotizing Fasciitis of Perineum):

• Extremely rare but life-threatening
• Requires immediate recognition and surgical intervention 8

Volume Depletion/Hypotension:

• Higher risk in elderly (≥65 years): 3.6% vs 2.2% placebo 8, 9
• Mitigation: Reduce diuretic dose in patients at risk for hypovolemia 1, 7
• Hold during "sick days" (dehydrating illness) 1

Acute Kidney Injury:

• Temporary eGFR reduction of 3-5 mL/min/1.73 m² (up to 15%) in first 4 weeks 1, 7
• Generally resolves within 1-3 months and represents hemodynamic changes, not true injury 1, 8
• Do not discontinue if eGFR dip follows this pattern 7
• Increased monitoring warranted in those at risk 1

Special Population Considerations

Elderly Patients (≥75 years):

• Higher discontinuation rate: 52% vs 33% in adults <75 years (P = 0.005) 10
• More adverse events: 31% vs 21% in younger adults (P <0.001) 10
• Efficacy maintained but requires closer monitoring 8

Renal Function Thresholds:

• DAPA-HF excluded: eGFR <30 mL/min/1.73 m² 1
• DAPA-CKD included: eGFR as low as 25 mL/min/1.73 m² 4, 8
• Current guidance: Can initiate down to eGFR ≥20 mL/min/1.73 m² for CKD/HF indications 7, 11
• Once initiated, do not discontinue if eGFR falls below initiation threshold during treatment 8
• For glycemic control alone without established CVD: not recommended when eGFR <45 mL/min/1.73 m² 8

Hypoglycemia Risk:

• Rarely causes hypoglycemia alone 1
• Requires dose reduction of insulin or secretagogues when added 1, 12
• Background therapies must be adjusted to prevent hypoglycemia 1

Laboratory Monitoring Pitfalls

Expected Changes (Not Concerning):

• Hematocrit increase: Mean +2.30% at 24 weeks (normal physiologic response) 8
• LDL cholesterol increase: Mean +2.5% to +2.9% at 24 weeks 8
• Initial eGFR dip: 3-5 mL/min/1.73 m² in first 4 weeks, then stabilizes 7, 8

Monitoring Interference:

• Urine glucose tests: Will be positive due to mechanism—use alternative methods 8
• 1,5-anhydroglucitol (1,5-AG) assay: Unreliable—use alternative methods 8

Implementation Algorithm

For HFrEF (LVEF ≤40%):

1. Initiate dapagliflozin 10 mg daily if eGFR ≥30 mL/min/1.73 m² 1
2. Start early in disease course, even before maximizing other GDMT 1
3. No need to wait for GDMT optimization—add immediately 1

For HFpEF (LVEF >40%):

1. Initiate dapagliflozin 10 mg daily for symptomatic patients 3
2. Benefits consistent across LVEF spectrum 3

For CKD (with or without diabetes):

1. Initiate if eGFR 20-75 mL/min/1.73 m² AND UACR ≥200 mg/g 4, 7, 11
2. Strong recommendation for albuminuric renal disease 1
3. Continue even if eGFR falls below 20 during treatment 8

For Type 2 Diabetes:

1. With established ASCVD: initiate to reduce HF hospitalization and death 1
2. Age >50 with CV risk factors: initiate to reduce HF hospitalization 1
3. Not recommended for glycemic control alone if eGFR <45 without established CVD 8

Recent Trial Update: DAPA ACT HF-TIMI 68 (2025)

In-hospital initiation in acute HF showed:

• Primary endpoint (CV death or worsening HF at 2 months): HR 0.86 (95% CI 0.68-1.08; P = 0.20)—not statistically significant 9
• However, meta-analysis of hospitalized HF patients showed benefit: HR 0.71 (95% CI 0.54-0.93; P = 0.012) for CV death/worsening HF 9
• All-cause mortality reduction: HR 0.57 (95% CI 0.41-0.80; P = 0.001) in meta-analysis 9
• Interpretation: Totality of evidence supports in-hospital initiation, though individual trial was neutral 9